<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03353831</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-OVAR 2.29</org_study_id>
    <nct_id>NCT03353831</nct_id>
  </id_info>
  <brief_title>Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer</brief_title>
  <official_title>Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AGO Research GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, randomized, partially blinded, multicenter trial to evaluate the&#xD;
      efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo&#xD;
      plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or&#xD;
      primary peritoneal cancer with 1st or 2nd relapse within 6 months after platinum based&#xD;
      chemotherapy or 3rd relapse.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 664 patients will be randomized in a 1:1 ratio to the treatments as specified&#xD;
      below:&#xD;
&#xD;
      Arm A: Chemotherapy + Bevacizumab + Placebo Arm B: Chemotherapy + Bevacizumab + Atezolizumab&#xD;
&#xD;
      Study treatment will continue until disease progression per RECIST v1.1, unacceptable&#xD;
      toxicity, or patient or investigator decision to discontinue treatment. Atezolizumab/placebo,&#xD;
      chemotherapy and bevacizumab may be discontinued for toxicity independently of each other in&#xD;
      the absence of disease progression.&#xD;
&#xD;
      For each patient, chemotherapy (PLD or Paclitaxel weekly) will be selected by the&#xD;
      investigator prior to randomization.&#xD;
&#xD;
      Recruitment to an individual chemotherapy cohort will be closed once 50% of patients are&#xD;
      recruited to this cohort. In such case the remaining cohort will remain open for recruitment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of randomizationrandomization to date of death from any cause assessed up to 40 months</time_frame>
    <description>regular patient contacts during the trial regarding life status</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever occurs earlier, assessed up to 40 months</time_frame>
    <description>Progressive Disease based on investigator assessment using RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient reported outcomes (QLQ and PRO-CTCAE)</measure>
    <time_frame>every 4 weeks during the first 3 months, then every 12 weeks until PD#1, assessed up to 40 months</time_frame>
    <description>questionnaires to be completed by patients and collected frequently during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever occurs earlier, assessed up to 40 months</time_frame>
    <description>based on investigator assessment using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever occurs earlier, assessed up to 40 months</time_frame>
    <description>based on investigator assessment using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy regarding PD-L1 status</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever occurs earlier, assessed up to 40 months</time_frame>
    <description>Efficacy regarding PD-L1 positivity defined by the VENTANA SP142 assay (negative: IC 0 versus positive IC: 1/2/3)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time from randomization to first subsequent therapy (TFST)</measure>
    <time_frame>at every visit during the trial up to a maximum of 40 months</time_frame>
    <description>time to first subsequent therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Time from randomization to second subsequent therapy (TSST)</measure>
    <time_frame>at every visit during the trial up to a maximum of 40 months</time_frame>
    <description>Time to second subsequent therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis on LDH levels at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>normal vs. elevated values</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">664</enrollment>
  <condition>Recurrent Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A: Chemotherapy + Bevacizumab + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Placebos q14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Chemotherapy + Bevacizumab + Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Atezolizumab 840 mg q14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab will be administered by intravenouse route at a dose of 10mg/kg q14 during the treatment period</description>
    <arm_group_label>Arm A: Chemotherapy + Bevacizumab + Placebo</arm_group_label>
    <arm_group_label>Arm B: Chemotherapy + Bevacizumab + Atezolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered by intravenous route at a dose of 840 mg q14 during the treatment period</description>
    <arm_group_label>Arm B: Chemotherapy + Bevacizumab + Atezolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Chemotherapy (Paclitaxel or PLD) will be administered by intravenous route at different doses during the treatment period q28</description>
    <arm_group_label>Arm A: Chemotherapy + Bevacizumab + Placebo</arm_group_label>
    <arm_group_label>Arm B: Chemotherapy + Bevacizumab + Atezolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo will be administered by intravenous route q14 during the treatment period</description>
    <arm_group_label>Arm A: Chemotherapy + Bevacizumab + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically diagnosed ovarian, fallopian tube, or primary peritoneal&#xD;
             cancer&#xD;
&#xD;
          2. Relapsed disease&#xD;
&#xD;
          3. Patients with up to three prior therapies. In patients with 1 or 2 prior treatment&#xD;
             lines, the treatment free interval after platinum has to be less than 6 months; in&#xD;
             addition patients with three prior lines of chemotherapy who are not considered for&#xD;
             platinum-containing chemotherapy lines are also eligible&#xD;
&#xD;
          4. Measurable disease, evaluable disease in combination with GCIG CA-125 criteria, or&#xD;
             histologically proven relapse/progression&#xD;
&#xD;
          5. Mandatory de novo tumor biopsy (not older than 3 months) sent to central laboratory as&#xD;
             formalin-fixed, paraffin-embedded (FFPE) sample for determination of PDL1 status prior&#xD;
             to randomization for stratification.&#xD;
&#xD;
          6. Availability of a representative archival FFPE tumor sample (preferable from primary&#xD;
             diagnosis)&#xD;
&#xD;
          7. Patient has not progressed on the chosen/planned chemotherapy (PLD or Paclitaxel) in&#xD;
             any prior line&#xD;
&#xD;
          8. Patients previously treated with bevacizumab are eligible, with the exclusion of those&#xD;
             patients that has suspended bevacizumab for more than 2 subsequent cycles or&#xD;
             permanently discontinued bevacizumab during their previous treatment due to toxicity.&#xD;
&#xD;
          9. Females aged ≥ 18 years at signing at time of signing informed consent form&#xD;
&#xD;
         10. Signed written informed consent and ability to comply with the study protocol, in the&#xD;
             investigator's judgement&#xD;
&#xD;
         11. Adequate hematological, renal and hepatic function within 28 days prior to first&#xD;
             administration of study treatment:&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 10xE^9/L&#xD;
&#xD;
               -  Platelet count ≥ 100 x 10xE^9/L&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase /Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT)&#xD;
                  and Alanine aminotransferase /Serum Glutamic Pyruvate Transaminase (ALAT/SGPT) ≤&#xD;
                  2.5 x ULN, unless liver metastases are present, in case of liver metastases&#xD;
                  values must be ≤ 5 x ULN&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x institutional ULN&#xD;
&#xD;
               -  Patient not receiving anticoagulant medication who has an International&#xD;
                  Normalized Ratio (INR) ≤ 1.5 and an Activated ProThrombin Time (aPTT) ≤ 1.5 x&#xD;
                  ULN. The use of full-dose oral or parenteral anticoagulants is permitted as long&#xD;
                  as the INR or aPTT is within therapeutic limits (according to site medical&#xD;
                  standard). If the patient is on oral anticoagulants, dose has to be stable for at&#xD;
                  least two weeks at the time of randomization&#xD;
&#xD;
               -  Urine dipstick for proteinuria &lt; 2+. If urine dipstick is ≥ 2+, 24-hours urine&#xD;
                  must demonstrate ≤ 1 g of protein in 24 hours.&#xD;
&#xD;
         12. Patients must have adequately controlled blood pressure (BP), with a systolic BP of ≤&#xD;
             140 mmHg and diastolic BP of ≤ 90 mmHg for eligibility. Patients must have a BP of ≤&#xD;
             140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior&#xD;
             to starting study.&#xD;
&#xD;
         13. Estimated life expectancy of at least 3 months&#xD;
&#xD;
         14. ECOG performance status 0 - 1&#xD;
&#xD;
         15. Negative urine or serum pregnancy test within 7 days of study treatment in women of&#xD;
             childbearing potential (WOCBP), confirmed prior to treatment on day 1&#xD;
&#xD;
         16. For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use a contraceptive method with a failure rate of &lt; 1%&#xD;
             per year during the treatment period and for at least 5 months after administration of&#xD;
             the last dose of atezolizumab/placebo and 6 months after the last dose of bevacizumab,&#xD;
             paclitaxel, or PLD, whichever is later.&#xD;
&#xD;
         17. For countries where this will apply to: a patient will be eligible for randomization&#xD;
             in this study only, if either affiliated to, or a beneficiary of a social security&#xD;
             category.&#xD;
&#xD;
         18. Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures, that include the completion of patient-reported&#xD;
             outcomes questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-epithelial tumor origin of the ovary, the fallopian tube or the peritoneum (i.e.&#xD;
             germ cell tumors)&#xD;
&#xD;
          2. Ovarian tumors of low malignant potential (e.g. borderline tumors)&#xD;
&#xD;
          3. Malignancies other than ovarian cancer within 5 years prior to randomisation, with the&#xD;
             exception of those with a negligible risk of metastasis or death (e.g., 5-year OS rate&#xD;
             &gt; 90%) and treated with expected curative outcome (such as adequately treated&#xD;
             carcinoma in situ of the cervix, non melanoma skin carcinoma, ductal carcinoma in&#xD;
             situ, or Stage I uterine cancer)&#xD;
&#xD;
          4. More than three prior systemic anticancer regimens; maintenance therapies (e.g. with&#xD;
             bevacizumab, olaparib or niraparib) are not calculated as separate line.&#xD;
&#xD;
          5. Prior systemic anticancer therapy within 28 days before randomization (except&#xD;
             bevacizumab: 20 days).&#xD;
&#xD;
          6. Prior radiotherapy to the pelvis or the abdomen.&#xD;
&#xD;
          7. Administration of other simultaneous chemotherapy drugs, any other anticancer therapy&#xD;
             or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial&#xD;
             treatment period (hormonal replacement thera-py is permitted).&#xD;
&#xD;
          8. Prior treatment with anti-CD137 or immune checkpoint blockade therapies, anti-PD1, or&#xD;
             anti-PD-L1 therapeutic antibodies or anti-CTLA 4&#xD;
&#xD;
          9. Prior randomization in AGO-OVAR 2.29.&#xD;
&#xD;
         10. Treatment with systemic immunostimulatory agents (in-cluding but not limited to&#xD;
             interferon-alpha (IFN-α) and interleukin-2 (IL-2) within 4 weeks or five half-lives of&#xD;
             the drug (whichever is longer) prior to cycle 1, day 1.&#xD;
&#xD;
         11. Treatment with systemic corticosteroids or other systemic immunosuppressive&#xD;
             medications (including but not limited to prednisone, dexamethasone,&#xD;
             cyclophos-phamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis&#xD;
             factor [TNF] agents) within 2 weeks prior to cycle 1, day 1, or anticipated&#xD;
             requirement for systemic immunosuppressive medications during the trial.&#xD;
&#xD;
             The use of inhaled corticosteroids for chronic obstruc-tive pulmonary disease,&#xD;
             mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension,&#xD;
             and low-dose supplemental corticosteroids for adrenocortical insufficiency are&#xD;
             allowed.&#xD;
&#xD;
         12. Patients with a history of allergic reaction to IV contrast requiring steroid&#xD;
             pre-treatment should have screening and subsequent tumor assessments performed using&#xD;
             magnetic resonance imaging (MRI).&#xD;
&#xD;
         13. Administration of a live, attenuated vaccine within 4 weeks prior to cycle 1, day 1 or&#xD;
             anticipation that such a live attenuated vaccine will be required during the study or&#xD;
             within 5 months after the last dose of atezolizumab/placebo. Influenza vaccination&#xD;
             should be given during influenza season only. Patients must not receive live,&#xD;
             attenuated influenza vaccination&#xD;
&#xD;
         14. Major surgery within 4 weeks of starting study treatment or patient who has not&#xD;
             completely recovered from the effects of any major surgery. Core biopsy or other minor&#xD;
             surgical procedure within 7 days prior to day 1, cycle 1 is permitted.&#xD;
&#xD;
         15. Previous allogeneic bone marrow transplant or previous solid organ transplantation.&#xD;
&#xD;
         16. Current treatment with anti-viral therapy for HBV.&#xD;
&#xD;
         17. History of idiopathic pulmonary fibrosis (including pneumonitis), organizing pneumonia&#xD;
             (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evi-dence of&#xD;
             active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the&#xD;
             radiation field (fibrosis) detected on screening chest CT scan is permitted&#xD;
&#xD;
         18. Previous Cerebro-Vascular Accident (CVA), Transient Ischemic Attack (TIA) or&#xD;
             Sub-Arachnoids Hemorrhage (SAH) within 6 months prior to randomization&#xD;
&#xD;
         19. History or evidence of thrombotic or hemorrhagic disorders within 6 months prior to&#xD;
             randomization&#xD;
&#xD;
         20. History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI&#xD;
             of the brain is mandatory (within 4 weeks prior to randomization) in case of&#xD;
             sus-pected brain metastases. Spinal MRI is mandatory (within 4 weeks prior to&#xD;
             randomization) in case of sus-pected spinal cord compression&#xD;
&#xD;
         21. History of autoimmune disease, including but not limited to dermatomyositis,&#xD;
             myasthenia gravis, myositis, auto-immune hepatitis, systemic lupus erythematosus,&#xD;
             rheu-matoid arthritis, inflammatory bowel disease, vascular thrombosis associated with&#xD;
             anti-phospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome,&#xD;
             Guil-lain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.&#xD;
             Except patients with:&#xD;
&#xD;
               -  a history of autoimmune hypothyroidism on a stable dose of thyroid replacement&#xD;
                  hormone&#xD;
&#xD;
               -  controlled type 1 diabetes mellitus on a stable insulin regimen&#xD;
&#xD;
             Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with&#xD;
             dermatologic manifestations only (e.g., patients with psoriatic arthritis are&#xD;
             excluded) are eligible for the study provided all of following conditions are met:&#xD;
&#xD;
               -  Rash must cover &lt; 10% of body surface area&#xD;
&#xD;
               -  Disease is well controlled at baseline and requires only low-potency topical&#xD;
                  corticosteroids&#xD;
&#xD;
               -  No occurrence of acute exacerbations of the underlying condition requiring&#xD;
                  psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents,&#xD;
                  oral calcineurin inhibitors, or high potency or oral corticosteroids within the&#xD;
                  previous 12 months&#xD;
&#xD;
         22. Any prior history of hypertensive crisis (CTCAE grade 4) or hypertensive&#xD;
             encephalopathy.&#xD;
&#xD;
         23. Immunocompromised patients, e.g., patients who are known to be serologically positive&#xD;
             for human immunodeficiency virus (HIV), patients with active hepatitis B (defined as&#xD;
             having a positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis&#xD;
             C.&#xD;
&#xD;
             Patients with past hepatitis B virus (HBV) infection or re-solved HBV infection&#xD;
             (defined as having a negative HBsAg test and a positive antibody to hepatitis B core&#xD;
             antigen [anti-HBc] antibody test) are eligible. Patients positive for hepatitis C&#xD;
             virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative&#xD;
             for HCV RNA.&#xD;
&#xD;
         24. Persistent toxicities (≥ CTCAE grade 2) with the exception of alopecia, caused by&#xD;
             previous cancer treatment. Neurotoxicity CTCAE grade 2 is permitted in case the&#xD;
             patient is planned for PLD treatment.&#xD;
&#xD;
         25. Severe infection requiring oral or IV antibiotics within 4 weeks prior to&#xD;
             randomization, including but not limited to active tuberculosis or hospitalization for&#xD;
             complications of infection, bacteremia, or severe pneumonia. Patients receiving&#xD;
             prophylactic antibiotics (e.g., to prevent urinary tract infection or chronic&#xD;
             obstructive pulmonary disease exacerbation) are eligible for the study.&#xD;
&#xD;
         26. Current or recent (within 10 days prior randomization) chronic use of aspirin &gt; 325&#xD;
             mg/day.&#xD;
&#xD;
         27. Clinically significant (e.g. active) cardiovascular disease, including:&#xD;
&#xD;
               -  Myocardial infarction or unstable angina pectoris within ≤ 6 months of&#xD;
                  randomization&#xD;
&#xD;
               -  New York Heart Association (NYHA) ≥ grade 2 congestive heart failure (CHF)&#xD;
&#xD;
               -  Poorly controlled cardiac arrhythmia despite medica-tion (patients with rate&#xD;
                  controlled atrial fibrillation are eligible)&#xD;
&#xD;
               -  Peripheral vascular disease grade ≥ 3 (e.g. symptomatic and interfering with&#xD;
                  activities of daily living [ADL] requiring repair or revision)&#xD;
&#xD;
               -  Resting ECG with QTc &gt;470 msec or family history of long QT syndrome&#xD;
&#xD;
         28. For patients with PLD treatment: Left ventricular ejection fraction defined by ECHO&#xD;
             below the institutional lower limit of normal&#xD;
&#xD;
         29. Evidence of bleeding diathesis or significant coagulopathy (in the absence of&#xD;
             anticoagulation).&#xD;
&#xD;
         30. Non-healing wound, active ulcer or bone fracture.&#xD;
&#xD;
         31. History of bowel obstruction (including subocclusive disease) related to underlying&#xD;
             disease, a history of ab-dominal fistula, GI perforation, or intra-abdominal abscess,&#xD;
             or evidence of deep infiltration of the bowel by pelvic examination or on computed&#xD;
             tomography, or clinical symptoms of bowel obstruction.&#xD;
&#xD;
         32. Patients with evidence of abdominal free air.&#xD;
&#xD;
         33. Evidence of any other disease, metabolic dysfunction, physical examination finding or&#xD;
             laboratory finding giving reasonable suspicion of disease or condition that&#xD;
             contraindicates the use of an investigational drug or puts the patient at high risk&#xD;
             for treatment related complications&#xD;
&#xD;
         34. Known hypersensitivity or allergy to drugs containing Chinese hamster (CHO) ovary&#xD;
             cells or history of severe allergic, anaphylactic, or other hypersensitivity reactions&#xD;
             to chimeric or humanized antibodies or fusion proteins&#xD;
&#xD;
         35. Known hypersensitivity reaction or allergy to drugs chemically related to bevacizumab,&#xD;
             paclitaxel, pegylated liposomal doxorubicin, or their excipients that contra-indicates&#xD;
             the subject's participation.&#xD;
&#xD;
         36. Patients considered a poor medical risk due to a serious, uncontrolled medical&#xD;
             disorder, non-malignant systemic disease or active, uncontrolled infection. This&#xD;
             includes also any psychiatric disorder that prohibits obtaining informed consent.&#xD;
&#xD;
         37. Pregnancy, lactation, or intention to become pregnant during the study or within 5&#xD;
             months after the last dose of atezolizumab/placebo as well as breastfeeding women or&#xD;
             intended to breastfeed during the study and up to 6 months after treatment with&#xD;
             paclitaxel, bevacizumab and pegylated liposomal doxorubicin (PLD).&#xD;
&#xD;
         38. For France only: Patients deprived of their liberty by judicial or administrative&#xD;
             decision and patients under a legal protection measure or unable to express their&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Harter, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kliniken Essen-Mitte, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadin Cron</last_name>
    <phone>+49 201 95 98 12</phone>
    <phone_ext>15</phone_ext>
    <email>ncron@ago-ovar.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Universiät Graz (MUG), Universitätsklinik für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edgar Petru</last_name>
    </contact>
    <investigator>
      <last_name>Edgar Petru</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Marth</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kepler Universitäts Klinikum (KUK), Universitätsklinik für Gynäkologie</name>
      <address>
        <city>Linz</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clemens Schmitt</last_name>
    </contact>
    <investigator>
      <last_name>Clemens Schmitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien (MUW) Universitätsklinik für Frauenheilkunde</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Polterauer</last_name>
    </contact>
    <investigator>
      <last_name>Stephan Polterauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint Jan</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eveline De Cuypere</last_name>
    </contact>
    <investigator>
      <last_name>Eveline De Cuypere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZA Edegem</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sevilay Altintas</last_name>
    </contact>
    <investigator>
      <last_name>Sevilay Altintas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint Lucas</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefanie De Waele</last_name>
    </contact>
    <investigator>
      <last_name>Stefanie De Waele</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Els Van Nieuwenhuysen</last_name>
    </contact>
    <investigator>
      <last_name>Els Van Nieuwenhuysen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Liège Sart Tilman Grivegnée</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Kridelka</last_name>
    </contact>
    <investigator>
      <last_name>Frédéric Kridelka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Henry</last_name>
    </contact>
    <investigator>
      <last_name>Stephanie Henry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Lamot</last_name>
    </contact>
    <investigator>
      <last_name>Caroline Lamot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Madsen</last_name>
    </contact>
    <investigator>
      <last_name>Kristine Madsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trine Zeeberg Iversen</last_name>
    </contact>
    <investigator>
      <last_name>Trine Zeeberg Iversen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Knudsen</last_name>
    </contact>
    <investigator>
      <last_name>Anja Knudsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zealand University Hospital</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jørn Herrstedt</last_name>
    </contact>
    <investigator>
      <last_name>Jørn Herrstedt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerli Kuusk</last_name>
    </contact>
    <investigator>
      <last_name>Gerli Kuusk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karin Grišan</last_name>
    </contact>
    <investigator>
      <last_name>Karin Grišan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henna Kärkkäinen</last_name>
    </contact>
    <investigator>
      <last_name>Henna Kärkkäinen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annika Auranen</last_name>
    </contact>
    <investigator>
      <last_name>Annika Auranen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SOPHIE ABADIE LACOURTOISIE</last_name>
    </contact>
    <investigator>
      <last_name>SOPHIE ABADIE LACOURTOISIE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Grenier</last_name>
    </contact>
    <investigator>
      <last_name>Julien Grenier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elsa Kalbacher</last_name>
    </contact>
    <investigator>
      <last_name>Elsa Kalbacher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blois Hospital (Centre Hospitalier de Blois)</name>
      <address>
        <city>Blois</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Arsene</last_name>
    </contact>
    <investigator>
      <last_name>Oliver Arsene</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique TIVOLI-DUCOS</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine GARBAY-DECOOPMAN</last_name>
    </contact>
    <investigator>
      <last_name>Delphine GARBAY-DECOOPMAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Floquet</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FLORENCE JOLY LOBBEDEZ</last_name>
    </contact>
    <investigator>
      <last_name>FLORENCE JOLY LOBBEDEZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Médipôle de Savoie</name>
      <address>
        <city>Challes-les-Eaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique Mille</last_name>
    </contact>
    <investigator>
      <last_name>Dominique Mille</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SASU Centre d'Oncologie et Radiothérapie 37</name>
      <address>
        <city>Chambray-lès-Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Combe</last_name>
    </contact>
    <investigator>
      <last_name>Pierre Combe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Sophie Dubois</last_name>
    </contact>
    <investigator>
      <last_name>Sophie Dubois</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-David Fumet</last_name>
    </contact>
    <investigator>
      <last_name>Jean-David Fumet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristell Taillandy</last_name>
    </contact>
    <investigator>
      <last_name>Kristell Taillandy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret, Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charlotte Bellier</last_name>
    </contact>
    <investigator>
      <last_name>Charlotte Bellier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ISABELLE RAY COQUARD</last_name>
    </contact>
    <investigator>
      <last_name>ISABELLE RAY COQUARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MICHEL FABBRO</last_name>
    </contact>
    <investigator>
      <last_name>MICHEL FABBRO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Azuréen de Cancérologie</name>
      <address>
        <city>Mougins</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>REMY LARGILLIER</last_name>
    </contact>
    <investigator>
      <last_name>REMY LARGILLIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ORACLE Centre d'Oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DOMINIQUE DOMINIQUE SPAETH</last_name>
    </contact>
    <investigator>
      <last_name>DOMINIQUE SPAETH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé du Confluent S.A.S</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALAIN LORTHOLARY</last_name>
    </contact>
    <investigator>
      <last_name>ALAIN LORTHOLARY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Follana</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Follana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional d'Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerome Jean Meunier</last_name>
    </contact>
    <investigator>
      <last_name>Jerome Jean Meunier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FREDERIC SELLE</last_name>
    </contact>
    <investigator>
      <last_name>FREDERIC SELLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JEROME ALEXANDRE</last_name>
    </contact>
    <investigator>
      <last_name>JEROME ALEXANDRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie Site Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel Rodrigues</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Rodrigues</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie Bonnin</last_name>
    </contact>
    <investigator>
      <last_name>Nathalie Bonnin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie</name>
      <address>
        <city>Plérin</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ANNE-CLAIRE HARDY BESSARD</last_name>
    </contact>
    <investigator>
      <last_name>ANNE-CLAIRE HARDY BESSARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie Site Saint Cloud</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel Rodrigues</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Rodrigues</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Collard</last_name>
    </contact>
    <investigator>
      <last_name>Olivier Collard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sakina SEKKATE</last_name>
    </contact>
    <investigator>
      <last_name>Sakina SEKKATE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur ONCOSUD</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MATHILDE MARTINEZ</last_name>
    </contact>
    <investigator>
      <last_name>MATHILDE MARTINEZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole - Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Gladieff</last_name>
    </contact>
    <investigator>
      <last_name>Laurence Gladieff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MARIE-CHRISTINE KAMINSKY</last_name>
    </contact>
    <investigator>
      <last_name>MARIE-CHRISTINE KAMINSKY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Pautier</last_name>
    </contact>
    <investigator>
      <last_name>Patricia Pautier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kreiskliniken Altötting-Burghausen</name>
      <address>
        <city>Altötting</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peer Hantschmann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacqueline Sagasser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hochtaunus-Kliniken</name>
      <address>
        <city>Bad Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Denschlag</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin (CVK)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Pietzner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antje Sperfeld</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Krebsheilkunde für Frauen</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gülten Oskay-Özcelik</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Egger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GYNAEKOLOGICUM Bremen</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Willibald Schröder</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustafa Aydogdu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sven Ackermann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Dessau</name>
      <address>
        <city>Dessau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hermann Voß</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Wimberger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiserswerther Diakonie</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Björn Lampe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Fehm</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Harter</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Buderath</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thorsten Kühn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt Höchst</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Rom</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed El-Balat</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zaher Alwafai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Gütersloh</name>
      <address>
        <city>Gütersloh</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wencke Ruhwedel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Halle/Saale</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Georg Strauß</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mammazentrum Hamburg am Krankenhaus Jerusalem</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Hilpert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Schmalfeldt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Schneeweiss</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft Frauenärzte am Bahnhofsplatz</name>
      <address>
        <city>Hildesheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Uleer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingo Runnebaum</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ViDia Christliche Kliniken Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Tomé</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Feisel-Schwickardi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikverbund Kempten-Oberallgäu</name>
      <address>
        <city>Kempten</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Felberbaum</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Bauerschlag</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Konstanz</name>
      <address>
        <city>Konstanz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Zorr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Kulmbach</name>
      <address>
        <city>Kulmbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benno Lex</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Köln</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Ratiu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bahriye Aktas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Hanker</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Kahl</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Almstedt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederik Marmé</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Kalder</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Griesshammer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Burges</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rotkreuzklinikum München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Pölcher</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Witteler</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Nordhausen</name>
      <address>
        <city>Nordhausen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Grafe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AGAPLESION Ev. Klinikum Schaumburg</name>
      <address>
        <city>Obernkirchen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Lemster</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum Offenburg-Gengenbach</name>
      <address>
        <city>Offenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidrun Männle</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Gropp-Meier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Seitz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum am Steinenberg</name>
      <address>
        <city>Reutlingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Negwer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thüringen Kliniken &quot;Georgius Agricola&quot;</name>
      <address>
        <city>Saalfeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietrich Hager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTS CaritasKlinikum Saarbrücken</name>
      <address>
        <city>Saarbrücken</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustafa Deryal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leopoldina-Krankenhaus</name>
      <address>
        <city>Schweinfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Weigel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Traunstein</name>
      <address>
        <city>Traunstein</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Zettl</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Mahlberg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hartkopf</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaus de Gregorio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Dr. Horst Schmidt Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Eichbaum</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marien-Hospital</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörn Treustedt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMO MVZ Wolfsburg</name>
      <address>
        <city>Wolfsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Liebrich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LSMU ligoninė Kauno klinikos</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arturas Inciura</last_name>
    </contact>
    <investigator>
      <last_name>Arturas Inciura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilniaus universiteto ligoninė Santaros klinikos</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Goda Jonuskiene</last_name>
    </contact>
    <investigator>
      <last_name>Goda Jonuskiene</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nacionalinis vėžio institutas</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BIRUTE BRASIUNIENE</last_name>
    </contact>
    <investigator>
      <last_name>BIRUTE BRASIUNIENE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Lindemann</last_name>
    </contact>
    <investigator>
      <last_name>Kristina Lindemann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia Gaba</last_name>
    </contact>
    <investigator>
      <last_name>Lydia Gaba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia (ICO) d'Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Pardo Burdalo</last_name>
    </contact>
    <investigator>
      <last_name>Beatriz Pardo Burdalo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Instituto de Oncología (VHIO)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Oaknin</last_name>
    </contact>
    <investigator>
      <last_name>Ana Oaknin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Jesus Rubio Perez</last_name>
    </contact>
    <investigator>
      <last_name>M. Jesus Rubio Perez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia (ICO) de Girona</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Barretina</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Jerez</name>
      <address>
        <city>Jerez De La Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Del Mar Gordon Santiago</last_name>
    </contact>
    <investigator>
      <last_name>M. Del Mar Gordon Santiago</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>La Paz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Redondo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra (CUN)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Gonzalez</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Gonzalez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Garcia Martinez</last_name>
    </contact>
    <investigator>
      <last_name>Elena Garcia Martinez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ester Villar</last_name>
    </contact>
    <investigator>
      <last_name>Ester Villar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Llàtzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Iglesias González</last_name>
    </contact>
    <investigator>
      <last_name>María Iglesias González</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra (CUN)</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Manuel Aramendia</last_name>
    </contact>
    <investigator>
      <last_name>Jose Manuel Aramendia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Lainez Milagro</last_name>
    </contact>
    <investigator>
      <last_name>Nuria Lainez Milagro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Alejandro Jose Alejandro Perez</last_name>
    </contact>
    <investigator>
      <last_name>Jose Alejandro Perez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología (IVO)</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Romero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Herrero Ibañez</last_name>
    </contact>
    <investigator>
      <last_name>Ana Herrero Ibañez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriel Lindahl</last_name>
    </contact>
    <investigator>
      <last_name>Gabriel Lindahl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Solna</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau AG</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Schreiber</last_name>
    </contact>
    <investigator>
      <last_name>Alexander Schreiber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tumor Zentrum Aarau</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RAZVAN POPESCU</last_name>
    </contact>
    <investigator>
      <last_name>RAZVAN POPESCU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Heubner</last_name>
    </contact>
    <investigator>
      <last_name>Martin Heubner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Kurzeder</last_name>
    </contact>
    <investigator>
      <last_name>Christian Kurzeder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Schwitter</last_name>
    </contact>
    <investigator>
      <last_name>Michael Schwitter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Frauenfeld</name>
      <address>
        <city>Frauenfeld</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MATHIAS FEHR</last_name>
    </contact>
    <investigator>
      <last_name>MATHIAS FEHR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>STEFAN AEBI</last_name>
    </contact>
    <investigator>
      <last_name>STEFAN AEBI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catrina Uhlmann Nussbaum</last_name>
    </contact>
    <investigator>
      <last_name>Catrina Uhlmann Nussbaum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Hasler-Strub</last_name>
    </contact>
    <investigator>
      <last_name>Ursula Hasler-Strub</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Andreas Müller</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Müller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Grabolus</last_name>
    </contact>
    <investigator>
      <last_name>Robert Grabolus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Lithuania</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent Ovarian Cancer</keyword>
  <keyword>Atezolizumab</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

